Αποτελέσματα αναζήτησης - "ПРОСТАТСПЕЦИФИЧЕСКИЙ МЕМБРАННЫЙ АНТИГЕН"

1

Academic Journal

Morphological assessment of the tubular glands of the nasopharyn ; Морфологическая оценка тубулярных желез носоглотки

Συγγραφείς: A. E. Orlov, O. I. Kaganov, M. M. Bondarenko, A. A. Makhonin, А. Е. Орлов, О. И. Каганов, М. М. Бондаренко, А. А. Махонин

Πηγή: Surgery and Oncology; Том 15, № 1 (2025); 49-53 ; Хирургия и онкология; Том 15, № 1 (2025); 49-53 ; 2949-5857

Θεματικοί όροι: тубариальные железы, positron emission tomography, computed tomography, prostate-specific membrane antigen, radiotherapy, salivary glands, tubarial glands, позитронно-эмиссионная томография, компьютерная томография, простатспецифический мембранный антиген, лучевая терапия, слюнные железы

Περιγραφή αρχείου: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/781/494; Семенов А.В., Гордон К.Б., Рожнов В.А. и др. Лучевая терапия локализованного рака гортани в режиме гиперфракционирования с равномерным дроблением дневной дозы. Радиация и риск (Бюллетень НРЭР) 2022;31(1):127–35. DOI:10.21870/0131-3878-2022-31-1-127-135; MacReady N. Looking treatment complications in the mouth. J Natl Cancer Inst 2013;105(2):76–7. DOI:10.1093/jnci/djs643; Nathan C.O., Asarkar A.A., Entezami P. et al. Current management of xerostomia in head and neck cancer patients. Am J Otolaryngol 2023;44(4):103867. DOI:10.1016/j.amjoto.2023.103867; Hopcraft M.S., Tan C. Xerostomia: an update for clinicians. Aust Dent J 2010;55(3):238–44;quiz 353. DOI:10.1111/j.1834-7819.2010.01229.x; Valstar M.H., de Bakker B.S., Steenbakkers R.J.H.M. et al. The tubarial salivary glands: A potential new organ at risk for radiotherapy. Radiother Oncol 2021;154:292–8. DOI:10.1016/j.radonc.2020.09.034; Pringle S., Bikker F.J., Vogel W. et al. Immunohistological profiling confirms salivary gland-like nature of the tubarial glands and suggests closest resemblance to the palatal salivary glands. Radiother Oncol 2023;187:109845. DOI:10.1016/j.radonc.2023.109845; Narayan R.K., Kumari C., Panchal P. et al. A macroscopic salivary gland and a potential organ or simply tubarial sero-mucinous glands? Radiother Oncol 2021;154:324–5. DOI:10.1016/j.radonc.2020.12.016; Schumann S. Salivary glands at the pharyngeal ostium of the eustachian tube are already described in histological literature. Radiother Oncol 2021;154:326. DOI:10.1016/j.radonc.2020.12.022; Mudry A., Jackler R.K. Are “tubarial salivary glands” a previously unknown structure? Radiother Oncol 2021;154:314–5. DOI:10.1016/j.radonc.2020.12.003; Li W., Wang J.W., Fang X. et al. Further comments on the tubarial glands. Radiother Oncol 2022;172:50–3. DOI:10.1016/j.radonc.2022.05.010; Sakthivel P., Thakar A., Arunraj S.T. et al. Physiological PSMA uptake in the tubarial salivary glands and its implications in the PARIS protocol-A first study of its kind! Clin Nucl Med 2021;46(8):e398–e405. DOI:10.1097/RLU.0000000000003583; Thakar A., Sakthivel P., Thankarajan Arunraj S. et al. Validation of postoperative angiofibroma radionuclide imaging study (PARIS) protocol using PSMA PET/CT-A proof of concept study. Clin Nucl Med 2021;46(5):e242–9. DOI:10.1097/RLU.0000000000003516; Pushpa N.B., Ravi K.S., Durgapal P. Discovery of new salivary gland – а substantial histological analysis. Radiother Oncol 2021;161:92–4. DOI:10.1016/j.radonc.2021.06.004; Holsinger F.C., Bui D.T. Anatomy, function, and evaluation of the salivary glands. Salivary gland disorders. Springer Berlin: Heidelberg, 2007. Pp. 1–16. DOI:10.1007/978-3-540-47072-4_1

Διαθεσιμότητα: https://www.onco-surgery.info/jour/article/view/781
https://doi.org/10.17650/2949-5857-2025-15-1-49-53

View record from BASE

2

Academic Journal

The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT ; Влияние предварительной гидратации пациентов на уровень физиологического накопления [18F]ПСМА-1007 в мочевом пузыре при ПЭТ/КТ

Συνεισφορές: this work was not funded., финансирование данной работы не проводилось.

Πηγή: Research and Practical Medicine Journal; Том 11, № 2 (2024); 8-21 ; Research'n Practical Medicine Journal; Том 11, № 2 (2024); 8-21 ; 2410-1893 ; 10.17709/2410-1893-2024-11-2

Θεματικοί όροι: мочевой пузырь, prostate-specific membrane antigen, PET/CT, [18F]PSMA-1007, hydration, pharmacokinetics, bladder, простатспецифический мембранный антиген, ПЭТ/КТ, [18F]ПСМА-1007, гидратация, фармакокинетика

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/1011/623; https://www.rpmj.ru/rpmj/article/view/1011/624; https://www.rpmj.ru/rpmj/article/downloadSuppFile/1011/1022; Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. https://doi.org/10.1002/ijc.33588 Epub ahead of print.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022, 252 с. Доступно по: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniyav-rossii-v-2021-g_zabolevaemost-i-smertnost.pdf. Дата обращения: 16.05.2024.; Wang R, Shen G, Huang M, Tian R. The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. Front Oncol. 2021 Jun 17;11:684629. https://doi.org/10.3389/fonc.2021.684629; Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11–20. https://doi.org/10.1007/s00259-013-2525-5; Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):92–101. https://doi.org/10.1007/s00259-016-3490-6; Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022 Jan;63(1):59–68. https://doi.org/10.2967/jnumed.121.263262; Носов Д. А., Волкова М. И., Гладков О. А., Карабина Е. В., Крылов В. В., Матвеев В. Б., и др. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли. 2022;12(3s2-1):607–626. https://doi.org/10.18027/2224-5057-2022-12-3s2-607-626; Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Cheng HH, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer. Version 1.2022 – September 10, 2021. Доступно по: www.nccn.org/patients.; Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119–1134. https://doi.org/10.1016/j.annonc.2020.06.011; Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 Jun 10;38(17):1963–1996. https://doi.org/10.1200/jco.19.02757; Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243–262. https://doi.org/10.1016/j.eururo.2020.09.042; Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013 Jun;76:55–62. https://doi.org/10.1016/j.apradiso.2012.06.034; Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678–688. https://doi.org/10.1007/s00259-016-3573-4; Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, et al. Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. J Nucl Med. 2017 Mar;58(3):425–431. https://doi.org/10.2967/jnumed.116.181768; Giesel FL, Cardinale J, Schäfer M, Neels O, Benešová M, Mier W, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1929– 1930. https://doi.org/10.1007/s00259-016-3447-9; Rahbar K, Weckesser M, Ahmadzadehfar H, Schäfers M, Stegger L, Bögemann M. Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076–1077. https://doi.org/10.1007/s00259-018-3952-0; Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466–1486. https://doi.org/10.1007/s00259-022-06089-w; Maisto C, Morisco A, de Marino R, Squame E, Porfidia V, D'Ambrosio L, et al. On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact. EJNMMI Radiopharm Chem. 2021 Oct 13;6(1):36. https://doi.org/10.1186/s41181-021-00150-z; Witkowska-Patena E, Giżewska A, Dziuk M, Miśko J, Budzyńska A, Walęcka-Mazur A. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):343–348. https://doi.org/10.1038/s41391-019-0194-6; Dang J, Yao Y, Li Y, Tan X, Ye Z, Zhao Y, et al. An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging. Front Med (Lausanne). 2023 Aug 31;10:1238333. https://doi.org/10.3389/fmed.2023.1238333; Allach Y, Banda A, van Gemert W, de Groot M, Derks Y, Schilham M, et al. An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. Cancers (Basel). 2022 Apr 21;14(9):2076. https://doi.org/10.3390/cancers14092076; Luurtsema G, Pichler V, Bongarzone S, Seimbille Y, Elsinga P, Gee A, Vercouillie J. EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality. EJNMMI Radiopharm Chem. 2021 Oct 9;6(1):34. https://doi.org/10.1186/s41181-021-00149-6; Soeda F, Watabe T, Naka S, Liu Y, Horitsugi G, Neels OC, et al. Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice. J Nucl Med. 2019 Nov;60(11):1594–1599. https://doi.org/10.2967/jnumed.118.223479; Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol. 2002 Apr;3(4):256–266. https://doi.org/10.1038/nrm778; https://www.rpmj.ru/rpmj/article/view/1011

Διαθεσιμότητα: https://www.rpmj.ru/rpmj/article/view/1011
https://doi.org/10.17709/2410-1893-2024-11-2-1

View record from BASE

3

Academic Journal

Modern possibilities of application 99mTc-labeled prostate-specific membrane antigen ligands in prostate cancer ; Современные возможности применения радиофармпрепаратов на основе лигандов к простатспецифическому мембранному антигену, меченных 99mTc, при раке предстательной железы

Συγγραφείς: A. V. Leontyev, A. I. Khalimon, M. T. Kuliev, A. Y. Govaleshko, A. D. Kaprin, A. A. Krasheninnikov, K. M. Nyushko, A. S. Kalpinskiy, B. Ya. Alekseev, А. В. Леонтьев, А. И. Халимон, М. Т. Кулиев, А. Ю. Говалешко, А. Д. Каприн, А. А. Крашенинников, К. М. Нюшко, А. С. Калпинский, Б. Я. Алексеев

Πηγή: Cancer Urology; Том 17, № 4 (2021); 136-150 ; Онкоурология; Том 17, № 4 (2021); 136-150 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: ПЭТ/КТ, salvage lymph node dissection, radioguided surgery, prostate-specific membrane antigen, 99m Tc-PSMA, SPECT/CT, PET/CT, спасительная лимфаденэктомия, радионавигационная хирургия, простатспецифический мембранный антиген, 99m Tc-ПСМА, ОФЭКТ/КТ

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1494/1339; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1046; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1047; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1048; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1049; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1050; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1051; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1494/1052; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.; Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).33. DOI:10.18027/2224-5057-2020-10-3s2-33.; Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53(2):227-30.; Silver D.A., Pellicer I., Fair W.R. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-5.; Barinka C., Sacha P., Sklenar J. et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004;13 (6):1627-35. DOI:10.1110/ps.04622104.; Cardinale J., Martin R., Remde Y. et al. Procedures for the GMP-compliant production and quality control of [(18)F] PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals (Basel) 2017;10(4):77. DOI:10.3390/ph10040077.; Alam I.S., Steinberg I., Vermesh O. et al. Emerging intraoperative imaging modalities to improve surgical precision. Mol Imaging Biol 2018;20(5):705-15. DOI:10.1007/s11307-018-1227-6.; Povoski S.P., Neff R.L., Mojzisik C.M. et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 2009;7:11. DOI:10.1186/1477-7819-7-11.; Bugby S.L., Lees J.E., Perkins A.C. Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook. Clin Transl Imaging 2017;5(4):323-41. DOI:10.1007/s40336-017-0235-x.; Orsaria P., Chiaravalloti A., Fiorentini A. et al. PET probe-guided surgery in patients with breast cancer: proposal for a methodological approach. In vivo 2017;31(1):101-10. DOI:10.21873/invivo.11031.; Werner P., Neumann C., Eiber M. et al. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res 2020;10:45.; Su H.C., Zhu Y., Ling G.W. et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian J Androl 2017;19(3):267-71. DOI:10.4103/1008-682X.192638.; Lawal I.O., Ankrah A.O., Mokgoro N.P. et al. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT. Prostate 2017;77(11):1205-12. DOI:10.1002/pros.23379.; Albalooshi B., Al sharhan M., Bagheri F. et al. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol 2020;8(1):1-7. DOI:10.22038/aojnmb.2019.43943.1293.; Langsteger W., Rezaee A., Pirich C., Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 2016;46(6):491-501. DOI:10.1053/j.semnuclmed.2016.07.003.; Lengana T., Lawal I.O., Boshomane T.G. et al. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 2018;16(5):392-401. DOI:10.1016/j.clgc.2018.07.009.; Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71. DOI:10.1016/j.eururo.2010.10.039.; Mottet N., van den Bergh R.C.N., Briers E. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer - 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79(2):243-62. DOI:10.1016/j.eururo.2020.09.042.; Tulsyan S., Das C.J., Tripathiet M. et al. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun 2017;38(12):1094-102. DOI:10.1097/MNM.0000000000000749.; Hofman M.S., Lawrentschuk N., Franci-set R.J. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395(10231):1208-16. DOI:10.1016/S0140-6736(20)30314-7.; Afshar-Oromieh A., Zechmann C.M., Malcher A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11-20. DOI:10.1007/s00259-013-2525-5.; Morigi J.J., Stricker P.D., van Leeuwen P.J. et al. Prospective comparison of 18Ffluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56(8):1185-90. DOI:10.2967/jnumed.115.160382.; Moghul M., Somani B., Lane T. et al. Detection rates of recurrent prostate cancer: 68gallium (Ga)-labelled prostatespecific membrane antigen versus choline PET/CT scans. A systematic review. Ther Adv Urol 2019;11:1756287218815793. DOI:10.1177/1756287218815793.; Briganti A., Giannarini G., Karnes R.J. et al. What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer? Eur Urol 2015;67(4):597-8. DOI:10.1016/j.eururo.2014.09.025.; Harke N.N., Godes M., Wagner C. et al. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial. World J Urol 2018;36(11):1817-23. DOI:10.1007/s00345-018-2330-7.; Grivas N., Wit E.M.K., Kuusk T. et al. The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on biochemical recurrence in prostate cancer patients treated with robot-assisted radical prostatectomy. J Nucl Med 2018;59(2):204-9. DOI:10.2967/jnumed.117.195644.; Muck A., Langesberg C., Mugler M. et al. Clinical outcome of patients with lymph node-positive prostate cancer following radical prostatectomy and extended sentinel lymph node dissection. Urol Int 2015;94(3):296-306. DOI:10.1159/000365011.; Eiber M., Fendler W.P., Rowe S.P. et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 2017;58(Suppl 2):67s-76s. DOI:10.2967/jnumed.116.186767.; Nagaya T., Nakamura Y.A., Choyke P.L., Kobayashi H. Fluorescence-guided surgery. Front Oncol 2017;7:314. DOI:10.3389/fonc.2017.00314.; Bravi C.A., Fossatia N., Gandaglia G. et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol 2020;78(5):661-9. DOI:10.1016/j.eururo.2020.06.043.; Claeys T., van Praet C., Lumen N. et al. Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome. Biomed Res Int 2015;2015:198543. DOI:10.1155/2015/198543.; Porres D., Pfister D., Thissen A. et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis 2017;20(1):85-92. DOI:10.1038/pcan.2016.54.; Knipper S., Tilki D., Mansholt J. et al. Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery. Eur Urol Focus 2019;5(1):50-3. DOI:10.1016/j.euf.2018.09.014.; Robu S., Schottelius M., Eiber M. et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med 2017;58:235-42. DOI:10.2967/jnumed.116.178939.; Schottelius M., Wirtz M., Eiber M. et al. [(111)In]PSMA-I&T:expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res 2015;5(1):68. DOI:10.1186/s13550-015-0147-6.; Maurer T., Robu S., Schottelius M. et al. 99mTc-based PSMA-radioguided surgery in recurrent prostate cancer. Eur Urol 2019;75(4):659-66. DOI:10.1016/j.eururo.2018.03.013.; Banerjee S.R., Pullambhatla M., Byun Y. et al. 68Ga-labeled inhibitors of prostatespecific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010;53(14):5333-41. DOI:10.1021/jm100623e.; Weineisen M., Schottelius M., Simecek J. et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 2015;56(8):1169-76. DOI:10.2967/jnumed.115.158550.; Benz P., Oberhausen E., Berberich R. Monoclonal antibody BW431/26 labelled with technetium 99m and indium 111: an investigation of the biodistribution and the dosimetry in patients. Eur J Nucl Med 1991;18(10):813-6. DOI:10.1007/BF00175060.; Bunschoten A., van den Berg N.S., Valdes Olmos R.A. et al. Tracers applied in radioguided surgery. In: Radioguided surgery - current applications and innovation directions in clinical practice. Eds.: K. Hermann, O.E. Nieweg, S.P. Povosiki. Heidelberg, Germany: Springer International Publishing, 2016.; Maurer T., Graefen M., van der Poel H. et al. Prostate-specific membrane antigen-guided surgery. J Nucl Med 2020;61(1):6-12. DOI:10.2967/jnumed.119.232330.; Kratzik C., Dorudi S., Schatzl M., Sinzinger H. Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer. Hell J Nucl Med 2018;21(3):202-4. DOI:10.1967/s002449910906.; Rauscher I., Duwel C., Wirtz M. et al. Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 2017;120(1):40-7. DOI:10.1111/bju.13713.; Horn T., Rauscher I., Eiber M. et al. PSMA-radioguided surgery in localised recurrent prostate cancer. Urologe A 2017;56(11):1417-23. DOI:10.1007/s00120-017-0516-z.; Van Leeuwen F.W., van der Poel H.G. Surgical guidance in prostate cancer: “from molecule to man” translations. Clin Cancer Res 2016;22(6):1304-6. DOI:10.1158/1078-0432.CCR-15-2575.; Jones A.D., Wilton J.C. Can intraoperative fluorescence play a significant role in hepatobiliary surgery? Eur J Surg Oncol 2017;43(9):1622-7. DOI:10.1016/j.ejso.2017.02.015.; Chen Y., Pullambhatla M., Banerjee S.R. et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem 2012;23(12):2377-85. DOI:10.1021/bc3003919.; Vahrmeijer A.L., Hutteman M., van der Vorst J.R. et al. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013;10(9):507-18. DOI:10.1038/nrclinonc.2013.123.; Fomina N., McFearin C.L., Sermsakdi M. et al. Low power, biologically benign NIR light triggers polymer disassembly. Macromolecules 2011;44(21):8590-7. DOI:10.1021/ma201850q.; Polom K., Murawa D., Rho Y.S. et al. Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review. Cancer 2011;117(21):4812-22. DOI:10.1002/cncr.26087.; Banerjee S.R., Foss C.A., Horhota A. et al. 111In- and IRDye800CW-labeled PLAPEG nanoparticle for imaging prostate-specific membrane antigen-expressing tissues. Biomacromolecules 2017;18(1):201-9. DOI:10.1021/acs.biomac.6b01485.; Baranski A.C., Schafer M., Bauder-Wust U. et al. PSMA-11-derived dual-labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-guided surgery of prostate cancer.J Nucl Med 2018;59:639-45. DOI:10.2967/jnumed.117.201293.; Schottelius M., Wurzer A., Wissmiller K. et al. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J Nucl Med 2019;60(1):71-8. DOI:10.2967/jnumed.118.212720.; Hensbergen A.W., Buckle T., van Willigen D.W. et al. Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction. J Nucl Med 2020;61(2):234-41. DOI:10.2967/jnumed.119.233064.; https://oncourology.abvpress.ru/oncur/article/view/1494

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1494
https://doi.org/10.17650/1726-9776-2021-17-4-136-150

View record from BASE

4

Academic Journal

Imaging standardization systems for hybrid PET imaging of prostate cancer with radiolabeled prostate-specific membrane antigen ligands: comparative review of PROMISE and PSMA-RADS version 1.0 ; Системы стандартизации оценки изображений при гибридной ПЭТ-визуализации рака предстательной железы с радиомечеными лигандами к простатспецифическому мембранному антигену: сравнительный обзор PROMISE и PSMA-RADS версии 1.0

Συγγραφείς: A. V. Leontyev, N. A. Rubtsova, A. I. Khalimon, M. T. Kuliev, I. V. Pylova, T. N. Lazutina, G. F. Khamadeeva, A. D. Kaprin, А. В. Леонтьев, Н. А. Рубцова, А. И. Халимон, М. Т. Кулиев, И. В. Пылова, Т. Н. Лазутина, Г. Ф. Хамадеева, А. Д. Каприн

Πηγή: Medical Visualization; № 2 (2019); 90-99 ; Медицинская визуализация; № 2 (2019); 90-99 ; 2408-9516 ; 1607-0763

Θεματικοί όροι: PSMA-RADS, biochemical recurrence, PET/CT, PET/MRI, prostate-specific membrane antigen, radiopharmaceuticals, PSMA ligands, PROMISE, PSMARADS, РПЖ, ПЭТ/КТ, ПЭТ/МРТ, простатспецифический мембранный антиген, радиофармпрепараты, лиганды к ПСМА

Περιγραφή αρχείου: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/775/552; Orel S.G., Kay N., Reynolds C., Sullivan D.C. BI-RADS categorization as a predictor of malignancy. Radiology. 1999; 221 (3): 845–850. http://doi.org/10.1148/radiology.211.3.r99jn31845. 2. Weinreb J.C., Barentsz J.O., Choyke P.L., Cornud F., Haider M.A., Macura K.J., Margolis D., Schnall M.D., Shtern F., Tempany C.M., Thoeny H.C., Verma S. PIRADS Prostate ImagingReporting and Data System: 2015, Version; Eur. Urol. 2016; 69 (1): 16–40. http://doi.org/10.1016/j.eururo.2015.08.052.; McKee B.J., Regis S.M., McKee A.B., Flacke S., Wald C. Performance of ACR LungRADS in a clinical CT lung screening program. J. Am. Coll. Radiol. 2015; 12 (3): 273–276. DOI:10.1016/j.jacr.2014.08.004; Purysko A.S., Remer E.M., Coppa C.P., Leão Filho H.M., Thupili C.R., Veniero J.C. LIRADS: a casebased review of the new categorization of liver findings in patients with endstage liver disease. Radiographics. 2012; 32 (7): 1977–1995. http://doi.org/10.1148/rg.327125026.; Tessler F.N., Middleton W.D., Grant E.G., Hoang J.K., Berland L.L., Teefey S.A., Cronan J.J., Beland M.D., Desser T.S., Frates M.C., Hammers L.W., Hamper U.M., Langer J.E., Reading C.C., Scoutt L.M., Stavros A.T. ACR thyroid imaging, reporting and data system (TIRADS): white Paper of the ACR TIRADS committee. J. Am. Coll. Radiol. 2017; 14 (5): 587–595. http://doi.org/10.1016/j.jacr.2017.01.046.; Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., Pruim J., Price P. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 1999; 35 (13): 1773–1782.; Wahl R., Jacene H., Kasamon Y., Lodge M. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (1): 122–150. http://doi.org/10.2967/jnumed.108.057307.; Cheson B., Fisher R., Barrington S. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and nonhodgkin lymphoma: the lugano classification. J. Clin. Oncol. 2014; 32 (27): 3059–3067. http://doi.org/10.1200/JCO.2013.54.8800.; Marcus Ch., Tahari A., Ciarallo A., Wahl R., Subramaniam R. Head and neck PET/CT: therapy response interpretation criteria (‘Hopkins criteria’). J. Nucl. Med. 2014; 55 (1): 344.; Rowe S., Pienta K., Pomper M., Gorin M. Structured Reporting System for ProstateSpecific Membrane Antigen-Targeted PET Imaging: PSMARADS Version 1.0. J. Nucl. Med. 2018; 59(3): 479–485. http://doi.org/10.2967/jnumed.117.195255.; Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W.A., Fendler W.P. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMALigand PET/CT. J. Nucl. Med. 2018; 59 (3): 469–478. http://doi.org/10.2967/jnumed.117.198119.; https://medvis.vidar.ru/jour/article/view/775

Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/775
https://doi.org/10.24835/1607-0763-2019-2-90-99

View record from BASE

5

Academic Journal

Application of radiolabeled ligands to the prostate-specific membrane antigen for determine localization of biochemical recurrence of prostate cancer by PET/CT (literature review) ; Применение радиомеченых лигандов к простатспецифическому мембранному антигену для определения локализации биохимического рецидива рака предстательной железы методом ПЭТ/КТ (обзор литературы)

Πηγή: Medical Visualization; № 3 (2018); 81-97 ; Медицинская визуализация; № 3 (2018); 81-97 ; 2408-9516 ; 1607-0763

Θεματικοί όροι: лиганды к ПСМА, biochemical recurrence, PET/CT, prostate-specific membrane antigen, radiopharmaceuticals, PSMA ligands, биохимический рецидив, ПЭТ/КТ, простатспецифический мембранный антиген, радиофармпрепараты

Περιγραφή αρχείου: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/578/483; McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 2016; 7 (2): 418–419. DOI:10.3945/an.116.012211.; Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann. Oncol. 2005; 16 (3): 481–488. DOI:10.1093/annonc/mdi098.; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Гер цена – филиал ФГБУ “НМИЦ радиологии” Минздрава России, 2018. 250 с.; Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Россий ской Федерации. Экспериментальная и клиническая урология. 2011. 2 (3): 6–7.; Freedland S.J., Presti Jr. J.C., Amling C.L., Kane C.J., Aronson W.J., Dorey F., Terris M.K.; SEARCH Database Study Group. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003; 61 (4): 736–741.; Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003; 169 (2): 517–523.; Chism D.B., Hanlon A.L., Horwitz E.M., Feigenberg S.J., Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57 (2): 270. DOI:10.1016/j.ijrobp.2003.10.059.; Kataja V.V., Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann. Oncol. 2005; 16 (1): i4–i36. DOI:10.1093/annonc/mdi826.; Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., van der Poel H.G., van der Kwast T.H., Rouvi re O., Wiegel T., Mottet N.EAU ESTRO SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration Resistant Prostate Cancer. Eur. Urol. 2017; 71 (4): 630–642. DOI:10.1016/j.eururo.2016.08.002.; Mottet N., Bellmunt J., Briers E., van den Bergh R.C.N., Bolla M., van Casteren N.J., Cornford P., Culine S., Joniau S., Lam T., Mason M.D., Matveev V., van der Poel H., van der Kwast T.H., Rouviиre O., Wiegel T. Guidelines on prostate cancer. Eur. Urol. 2015; 137 p.; Асланиди И.П., Пурсанова Д.М., Мухортова О.В., Сильченков А.В., Рощин Д.А., Корякин А.В., Иванов С.А., Широкорад В.И. ПЭТ / КТ с 11С-холином в диагностике рецидива рака предстательной железы у пациентов с биохимическим прогрессированием. Онкоурология. 2015; 11 (3): 79–86. DOI:10.17650/1726-9776-2015-11-3-79-86.; Deliveliotis C., Manousakas T., Chrisofos M., Skolarikos A., Delis A., Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. Wld J. Urol. 2007; 25 (3): 309–313. DOI:10.1007/s00345-007-0167-6.; Heidenreich A., Bastian P.J., Bellmunt J, Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., Mottet N.; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2014; 65: 467–479. DOI:10.1016/j.eururo.2013.11.002.; Apolo A.B., Pandit-Taskar N., Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer. J. Nucl. Med. 2008; 49 (12): 2031–2041. DOI:10.2967/jnumed.108.050658.; Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010; 254 (3): 925–933. DOI:10.1148/radiol.09090413.; Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., Holland-Letz T., Hadaschik B.A., Giesel F.L., Debus J., Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014; 41 (1): 11–20. DOI:10.1007/s00259-013-2525-5.; Schmid D., John H., Zweifel R., Cservenyak T., Westera G., Goerres G.W., von Schulthess G.K., Hany T.F. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005; 235 (2): 623–628. DOI:10.1148/radiol.2352040494.; Schwenck J., Rempp H., Reischl C., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Foug re C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92 – 101. DOI:10.1007/s00259-016-3490-6.; Kitajima K., Murphy R.C., Nathan M.A., Froemming A.T., Hagen C.E., Takahashi N., Kawashima A. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J. Nucl. Med. 2014; 55 (2): 223–232. DOI:10.2967/jnumed.113.123018.; Ceci F., Castellucci P., Graziani T., Schiavina R., Chondrogiannis S., Bonfiglioli R., Costa S., Virgolini I.J., Rubello D., Fanti S., Colletti P.M. 11C-Choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin. Nucl. Med. 2015; 40 (5): 265–270. DOI:10.1097/RLU.0000000000000783.; Nanni C., Schiavina R., Brunocilla E., Boschi S., Borghesi M., Zanoni L., Pettinato C., Martorana G., Fanti S. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. Clin. Nucl. Med. 2015; 40 (8): 386–391. DOI:10.1097/RLU.0000000000000849.; Evangelista L., Briganti A., Fanti S., Joniau S., Reske S., Schiavina R., Stief C., Thalmann G.N., Picchio M. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur. Urol. 2016; 70 (1): 161–175. DOI:10.1016/j.eururo.2016.01.029.; Calais J., Kisntialhan A.U., Cap M., Fendler W.P., Eiber M., Herrmann K., Ceci F., Reiter R.E., Rettig M.B., Hegde J.V., Shaverdian N., King C.R., Steinberg M.L., Czernin J., Nickols N.G. Potential impact of 68Ga-PSMA-11 PET/ CT on prostate cancer definitive radiation therapy planning. J. Nucl. Med. 2018. DOI:10.2967/jnumed.118.209387.; Calais J., Fendler W.P., Herrmann K., Eiber M., Ceci F. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J. Nucl. Med. 2017. DOI:10.2967/jnumed.117.203257.; Sonni I., Baratto L., Iagaru A. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin. PET Clin. 2017; 12 (2): 159–171. DOI:10.1016/j.cpet.2016.11.003.; Skovgaard D., Persson M., Kjaer A. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. PET Clin. 2017; 12 (2): 243–255. DOI:10.1016/j.cpet.2016.12.005.; Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7: 27–935.; Barinka C., Sбcha P., Sklenбr J., Man P., Bezouska K., Slusher B.S., Konvalinka J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci. 2004; 13 (6): 1627– 1635. DOI:10.1110/ps.04622104.; Witkowska-Patena E., Mazurek A., Dziuk M. 68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now? Cent. Eur. J. Urol. 2017; 70 (1): 37–43. DOI:10.5173/ceju.2017.947.; Sokoloff R.L., Norton K.C., Gasior C.L., Marker K.M., Grauer L.S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate. 2000; 150 (2): 150–157.; Kahn D., Williams R.D., Haseman M.K., Reed N.L., Miller S.J., Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromabpendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J. Clin. Oncol. 1998; 16 (1): 284–289.; Bander N.H., Trabulsi E.J., Kostakoglu L., Yao D., Vallabhajosula S., Smith-Jones P., Joyce M.A., Milowsky M., Nanus D.M., Goldsmith S.J. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 2003; 170 (1): 1717–1721. DOI:10.1097/01.ju.0000091655.77601.0c; Власова О.П., Герман К.Э., Крылов В.В., Петриев В.М., Эпштей н Н.Б. Новые радиофармпрепараты для диагностики и терапии метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник РАМН. 2015. 70 (3): 360–365. DOI:10.15690/vramn.v70i3.1334.; Meredith G., Wong D., Yaxley J.Coughlin G., Thompson L., Kua B., Gianduzzo T. The use of 68Ga PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016; 118 (3): 49–55. DOI:10.1111/bju.13616.; Eder M., Schдfer M., Bauder-Wьst U., Hull W.E., Wдngler C., Mier W., Haberkorn U., Eisenhut M. 68Gacomplex lipophilicity and the targeting property of a ureabased PSMA inhibitor for PET imaging. Bioconjugate Chem. 2012; 23 (4): 688–697. DOI:10.1021/bc200279b.; Eder M., Neels O., Mьller M., Bauder-Wьst U., Remde Y., Schдfer M., Hennrich U., Eisenhut M., Afshar-Oromieh A., Haberkorn U., Kopka K. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014; 30 (7): 779–796. DOI:10.3390/ph7070779.; McCarthy M., Langton T., Kumar D., Campbell A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1455–1462. DOI:10.1007/s00259-017-3699-z.; Afshar-Oromieh A., Haberkorn U., Eder M., Eisenhut M., Zechmann C.M. [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (6): 1085–1086. DOI:10.1007/s00259-012-2069-0.; Afshar-Oromieh A., Malcher A., Eder M., Eisenhut M., Linhart H.G., Hadaschik B.A., Holland-Letz T., Giesel F.L., Kratochwil C., Haufe S., Haberkorn U., Zechmann C.M. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 2013; 40 (4): 486–495. DOI:10.1007/s00259-012-2298-2.; Afshar-Oromieh A., Hetzheim H., Kьbler W., Kratochwil C., Giesel F.L., Hope T.A., Eder M., Eisenhut M., Kopka K., Haberkorn U. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (9): 1611–1620. DOI:10.1007/s00259-016-3419-0.; Afshar-Oromieh A., Sattler L.P., Mier W., Hadaschik B.A., Debus J., Holland-Letz T., Kopka K., Haberkorn U. The clinical impact of additional late PET/ CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J. Nucl. Med. 2017; 58 (5): 750–755. DOI:10.2967/jnumed.116.183483.; Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Kratochwil C., Mier W., Haufe S., Debus N., Eder M., Eisenhut M., Schдfer M., Neels O., Hohenfellner M., Kopka K., Kauczor H.U., Debus J., Haberkorn U. Diagnostic performance of (68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1258–1268. DOI:10.1007/s00259-017-3711-7.; Perera M., Papa N., Christidis D., Wetherell D., Hofman M.S., Murphy D.G., Bolton D., Lawrentschuk N. Specificity, and Predictors of Positive (68)Ga-Prostatespecific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. 2016; 70 (6): 926–937. DOI:10.1016/j.eururo.2016.06.021.; Roach P.J., Francis R., Emmett L., Hsiao E., Kneebone A., Hruby G., Eade T., Nguyen Q.A., Thompson B.D., Cusick T., McCarthy M., Tang C., Ho B., Stricker P.D., Scott A.M. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018; 59 (1): 82–88. DOI:10.2967/jnumed.117.197160.; Albisinni S., Artigas C., Aoun F., Biaou I., Grosman J., Gil T., Hawaux E., Limani K., Otte F.X., Peltier A., Sideris S., Sirtaine N., Flamen P., van Velthoven R. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120 (2): 197–203. DOI:10.1111/bju.13739.; Sahlmann C.O., Meller B., Bouter C., Ritter C.O., Strцbel P., Lotz J., Trojan L., Meller J., Hijazi S. Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (5): 895–905. DOI:10.1007/s00259-015-3251-y.; Kabasakal L., Demirci E., Ocak M., Akyel R., Nematyazar J., Aygun A., Halac M., Talat Z., Araman A. Evaluation of PSMA PET/CT imaging using a 68GaHBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015; 36 (6): 582–587. DOI:10.1097/MNM.0000000000000290.; Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl. Radiat. Isot. 2013; 76: 55–62. DOI:10.1016/j.apradiso.2012.06.034.; Mease R.C., Dusich C.L., Foss C.A., Ravert H.T., Dannals R.F., Seidel J., Prideaux A., Fox J.J., Sgouros G., Kozikowski A.P., Pomper M.G. N-[N-[(S)-1,3-dicarboxypro pyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin. Cancer Res. 2008; 14 (10): 3036 – 3043. DOI:10.1158/1078-0432.CCR-07-1517.; Cho S.Y., Gage K.L., Mease R.C., Senthamizhchelvan S., Holt D.P., Jeffrey-Kwanisai A., Endres C.J., Dannals R.F., Sgouros G., Lodge M., Eisenberger M.A., Rodriguez R., Carducci M.A., Rojas C., Slusher B.S., Kozikowski A.P., Pomper M.G. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecularweight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 2012; 53 (12): 1883–1891. DOI:10.2967/jnumed.112.104661.; Szabo Z., Mena E., Rowe S.P., Plyku D., Nidal R., Eisenberger M.A., Antonarakis E.S., Fan H., Dannals R.F., Chen Y., Mease R.C., Vranesic M., Bhatnagar A., Sgouros G., Cho S.Y., Pomper M.G.Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol. Imaging Biol. 2015; 17 (4): 565–574. DOI:10.1007/s11307-015-0850-8.; Chen Y., Pullambhatla M., Foss C.A., Byun Y., Nimmagadda S., Senthamizhchelvan S., Sgouros G., Mease R.C., Pomper M.G. 2-(3-{1-Carboxy-5-[(6-[18F]fluoropyridine3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 2011; 17 (24): 7645– 7653. DOI:10.1158/1078-0432.CCR-11-1357.; Rowe S.P., Macura K.J., Mena E., Blackford A.L., Nadal R., Antonarakis E.S., Eisenberger M., Carducci M., Fan H., Dannals R.F., Chen Y., Mease R.C., Szabo Z., Pomper M.G., Cho S.Y. PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol. Imaging Biol. 2016; 18 (3): 411–419. DOI:10.1007/s11307-016-0957-6.; Dietlein F., Kobe C., Neubauer S., Schmidt M., Stockter S., Fischer T., Schomдcker K., Heidenreich A., Zlatopolskiy B.D., Neumaier B., Drzezga A., Dietlein M. PSA-stratified performance of 18Fand 68Ga-labeled tracers in PSMAPET imaging of patients with biochemical recurrence of prostate cancer. J. Nucl. Med. 2017; 58 (6): 947–952. DOI:10.2967/jnumed.116.185538.; Dietlein M., Kobe C., Kuhnert G., Stockter S., Fischer T., Schomдcker K., Schmidt M., Dietlein F., Zlatopolskiy B.D., Krapf P., Richarz R., Neubauer S., Drzezga A., Neumaier B. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMAHBEDCC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol. Imaging Biol. 2015; 17 (4): 575–584. DOI:10.1007/s11307-015-0866-0.; Cardinale J., Schafer M., Benesova M., Bauder-Wьst U., Leotta K., Eder M., Neels O.C., Haberkorn U., Giesel F.L., Kopka K. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen Ligand for prostate cancer imaging. J. Nucl. Med. 2017; 58 (3) 425–431. DOI:10.2967/jnumed.116.181768.; Kesch C., Vinsensia M., Radtke J.P., Schlemmer H.P., Heller M., Ellert E., Holland-Letz T., Duensing S., Grabe N., Afshar-Oromieh A., Wieczorek K., Schдfer M., Neels O.C., Cardinale J., Kratochwil C., Hohenfellner M., Kopka K., Haberkorn U., Hadaschik B.A., Giesel F.L. Intraindividual comparison of 18F-PSMA-1007-PET/ CT, multiparametric MRI and radical prostatectomy specimen in patients with primary prostate cancer – a retrospective, proof of concept study. J. Nucl. Med. 2017; 58 (11): 1805–1810. DOI:10.2967/jnumed.116.189233.; Giesel F.L., Kesch C., Yun M., Cardinale J., Haberkorn U., Kopka K., Kratochwil C., Hadaschik B.A. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin. Genitourin Cancer. 2017; 15 (3): 497–499. DOI:10.1016/j.clgc.2016.12.029.; Giesel F.L., Hadaschik B., Cardinale J., Radtke J., Vinsensia M., Lehnert W., Kesch C., Tolstov Y., Singer S., Grabe N., Duensing S., Schдfer M., Neels O.C., Mier W., Haberkorn U., Kopka K., Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (4): 678–688. DOI:10.1007/s00259-016-3573-4.; Beheshti M., Rezaee A., Langsteger W. 68Ga-PSMA-HBED uptake on Cervicothoracic (Stellate) ganglia, a common pitfall on PET/ CT. Clin. Nucl. Med. 2017; 42 (3): 195–196. DOI:10.1097/RLU.0000000000001518.; Krohn T., Verburg F.A., Pufe T., Neuhuber W., Vogg A., Heinzel A., Mottaghy F.M., Behrendt F.F. [(68)Ga]PSMAHBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42 (2): 210–214. DOI:10.1007/s00259-014-2915-3.; Rischpler C., Beck T.I., Okamoto S., Schlitter A.M., Knorr K., Schwaiger M., Gschwend J., Maurer T., Meyer P.T., Eiber M. 68Ga-PSMA-HBED-CC ligand uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging. J. Nucl. Med. 2018. DOI:10.2967/jnumed.117.204677.; Laidler P., Dulinska J., Lekka M., Lekki J. Expression of prostate specific membrane antigen in androgenindependent prostate cancer cell line PC-3. Arch. Biochem.Biophys. 2005; 435 (1): 1–14. DOI:10.1016/j.abb.2004.12.003.; Parimi V., Goyal R., Poropatich K., Yang X.J. Neuroendocrine differentiation of prostate cancer: a review. Am. J. Clin. Exp. Urol. 2014; 2 (4): 273–285.; Yuan T.C., Veeramani S., Lin M.F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr.Relat. Cancer. 2007; 14: 531–547. DOI:10.1677/ERC-07-0061.; Gorin M.A., Pomper M.G., Rowe S.P. PSMA-targeted imaging of prostate cancer: the best is yet to come. BJU Int. 2016; 117 (5): 715–716. DOI:10.1111/bju.13435.; Rowe S.P., Gorin M.A., Salas F., Drzezga A., Pomper M.G. Clinical experience with 18F-labeled small molecule inhibitors of prostate-specific membrane antigen. PET Clin. 2017; 12 (2): 235–241. DOI:10.1016/j.cpet.2016.12.006.; Silver D.A., Pellicer I., Fair W.R., Heston W.D., CordonCardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997; 3 (1): 81–85.; Ristau B.T., O'Keefe D.S., Bacich D.J. The prostatespecific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol. 2014; 32 (3): 372–379. DOI:10.1016/j.urolonc.2013.09.003.; Sheikhbahaei S., Afshar-Oromieh A., Eiber M., Solnes L.B., Javadi M.S., Ross A.E., Pienta K.J., Allaf M.E., Haberkorn U., Pomper M.G., Gorin M.A., Rowe S.P. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (12): 2117–2136. DOI:10.1007/s00259-017-3780-7.; Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W.A., Fendler W.P. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/ CT. J. Nucl. Med. 2018; 59 (3): 469–478. DOI:10.2967/jnumed.117.198119.; https://medvis.vidar.ru/jour/article/view/578

Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/578
https://doi.org/10.24835/1607-0763-2018-3-81-97

View record from BASE

6

Academic Journal